Linna Wang

2.9k total citations · 1 hit paper
32 papers, 1.1k citations indexed

About

Linna Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Linna Wang has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Hepatology. Recurrent topics in Linna Wang's work include Cancer Immunotherapy and Biomarkers (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers) and Neurological Disease Mechanisms and Treatments (5 papers). Linna Wang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers) and Neurological Disease Mechanisms and Treatments (5 papers). Linna Wang collaborates with scholars based in China, United States and Romania. Linna Wang's co-authors include Jianjun Zou, Shukui Qin, Jianping Xiong, Zhiqiang Meng, Zhendong Chen, Zhenggang Ren, Yuxian Bai, Xiaohong Chen, Xiaoli Chai and Weijia Fang and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Physical Chemistry B and The Lancet Oncology.

In The Last Decade

Linna Wang

32 papers receiving 1.1k citations

Hit Papers

Camrelizumab in patients with previously treated advanced... 2020 2026 2022 2024 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
    2020 418 citations Shukui Qin, Zhenggang Ren et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Linna Wang China 16 581 387 278 209 204 32 1.1k
Makoto Akaike Japan 24 750 1.3× 219 0.6× 362 1.3× 336 1.6× 165 0.8× 90 1.5k
Meihua Wang China 15 404 0.7× 154 0.4× 269 1.0× 213 1.0× 57 0.3× 39 1.3k
Hao‐Wei Teng Taiwan 21 788 1.4× 130 0.3× 254 0.9× 189 0.9× 231 1.1× 73 1.4k
Huanyu Zhao China 18 429 0.7× 186 0.5× 333 1.2× 141 0.7× 141 0.7× 69 1.3k
Jun Luo China 19 283 0.5× 584 1.5× 192 0.7× 229 1.1× 241 1.2× 67 1.4k
Lechi Ye China 18 628 1.1× 354 0.9× 396 1.4× 241 1.2× 93 0.5× 48 1.4k
Pál Kaposi-Novák United States 12 384 0.7× 764 2.0× 147 0.5× 284 1.4× 206 1.0× 15 1.6k
Genís Campreciós Spain 12 437 0.8× 532 1.4× 276 1.0× 229 1.1× 131 0.6× 25 1.4k
Minoru Shigekawa Japan 19 315 0.5× 200 0.5× 107 0.4× 230 1.1× 73 0.4× 63 1.2k

Countries citing papers authored by Linna Wang

Since Specialization
Citations

This map shows the geographic impact of Linna Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linna Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linna Wang more than expected).

Fields of papers citing papers by Linna Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linna Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linna Wang. The network helps show where Linna Wang may publish in the future.

Co-authorship network of co-authors of Linna Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Linna Wang. A scholar is included among the top collaborators of Linna Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linna Wang. Linna Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Zhao, Haiyu, Mengxiao Wang, Mengyao Tian, et al.. (2023). Huanglian Jiedu Wan intervened with “Shi-Re Shanghuo” syndrome through regulating immune balance mediated by biomarker succinate. Clinical Immunology. 258. 109861–109861. 1 indexed citations
4.
Ni, Ping, Yingying Xu, Linna Wang, et al.. (2023). Evaluation of therapeutic benefits of botulinum toxin for foot dystonia associated with Parkinson's disease. Toxicon. 238. 107587–107587. 4 indexed citations
5.
Jiang, Shan, Yan Zhang, Jiayin Han, et al.. (2023). The immediate adverse drug reactions induced by ShenMai Injection are mediated by thymus-derived T cells and associated with RhoA/ROCK signaling pathway. Frontiers in Immunology. 14. 1135701–1135701. 5 indexed citations
6.
Feng, Jifeng, Jing Wang, Qi Zhou, et al.. (2022). SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study. Clinical Cancer Research. 28(24). 5297–5305. 42 indexed citations
7.
Li, Linji, et al.. (2022). Machine learning prediction of postoperative unplanned 30-day hospital readmission in older adult. Frontiers in Molecular Biosciences. 9. 910688–910688. 7 indexed citations
8.
Peng, Zhi, Jia Wei, Wang Feng, et al.. (2021). Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 27(11). 3069–3078. 75 indexed citations
9.
Qin, Shukui, Shanzhi Gu, Zhenggang Ren, et al.. (2021). Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. International Journal of Cancer. 149(11). 1944–1954. 38 indexed citations
10.
Li, Hui, Shukui Qin, Ying Liu, et al.. (2021). Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Drug Design Development and Therapy. Volume 15. 1873–1882. 25 indexed citations
11.
Ren, Zhenggang, Shukui Qin, Zhiqiang Meng, et al.. (2021). A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. Liver Cancer. 10(5). 500–509. 16 indexed citations
12.
Qin, Shukui, Zhenggang Ren, Zhiqiang Meng, et al.. (2020). Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. The Lancet Oncology. 21(4). 571–580. 418 indexed citations breakdown →
13.
Wang, Feng, Shukui Qin, Xinchen Sun, et al.. (2020). Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. Journal of Hematology & Oncology. 13(1). 97 indexed citations
14.
Liu, Dong, Yichun Ning, Ying Zhang, et al.. (2018). Youthful systemic milieu alleviates renal ischemia-reperfusion injury in elderly mice. Kidney International. 94(2). 268–279. 32 indexed citations
15.
Wang, Linna, Chen Cai, & Yunhong Zhang. (2017). Kinetically Determined Hygroscopicity and Efflorescence of Sucrose–Ammonium Sulfate Aerosol Droplets under Lower Relative Humidity. The Journal of Physical Chemistry B. 121(36). 8551–8557. 18 indexed citations
16.
Li, Tingting, et al.. (2015). The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats. Acta Pharmacologica Sinica. 36(8). 917–927. 51 indexed citations
17.
Wang, Linna, et al.. (2014). Expression of RUNX3 and β-catenin in the carcinogenesis of sporadic colorectal tubular adenoma. Tumor Biology. 35(6). 6039–6046. 2 indexed citations
18.
Wang, Xiaoli, Linna Wang, Zhangjian Huang, et al.. (2013). Synthesis and biological evaluation of nitric oxide releasing derivatives of 6-amino-3-n-butylphthalide as potential antiplatelet agents. Bioorganic & Medicinal Chemistry Letters. 23(7). 1985–1988. 19 indexed citations
19.
Wang, Xiaoli, Linna Wang, Tingting Li, et al.. (2013). Novel Hybrids of Optically Active Ring-Opened 3-n-Butylphthalide Derivative and Isosorbide as Potential Anti-Ischemic Stroke Agents. Journal of Medicinal Chemistry. 56(7). 3078–3089. 38 indexed citations
20.
Wang, Linna, et al.. (2008). [Effect of enalapil on renal interstitial fibrosis in rats with unilateral ureteral obstruction].. PubMed. 33(9). 841–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Makoto Akaike Breakdown of academic impact, for papers by Meihua Wang Breakdown of academic impact, for papers by Hao‐Wei Teng Breakdown of academic impact, for papers by Huanyu Zhao Breakdown of academic impact, for papers by Jun Luo Breakdown of academic impact, for papers by Lechi Ye Breakdown of academic impact, for papers by Pál Kaposi-Novák Breakdown of academic impact, for papers by Genís Campreciós Breakdown of academic impact, for papers by Minoru Shigekawa
Rankless by CCL
2026